Replimune wins FDA approval after melanoma drug was twice rejectednews2026-08-06T20:03:38+00:00August 6th, 2026|Endpoints News|
FDA details pilot plan to expedite new drugs, eyeing up to 10 programsnews2026-08-06T19:16:03+00:00August 6th, 2026|Endpoints News|
Judge signs off on Teva’s $35M settlement over delayed inhaler genericsnews2026-08-06T19:04:09+00:00August 6th, 2026|Endpoints News|
Intellia identifies genetic risk factor for liver complications in CRISPR trialnews2026-08-06T15:33:40+00:00August 6th, 2026|Endpoints News|
Sarepta pushes back Elevidys timeline; Emergent lays off 90 staffersnews2026-08-06T13:55:00+00:00August 6th, 2026|Endpoints News|
Tarsus bets $450M on Alkeus’ Stargardt drugnews2026-08-06T12:57:19+00:00August 6th, 2026|Endpoints News|
Merck KGaA readies tariff refunds worth €40M for life science customersnews2026-08-06T11:30:19+00:00August 6th, 2026|Endpoints News|
Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapynews2026-08-06T11:00:43+00:00August 6th, 2026|Endpoints News|
Greg Verdine’s LifeMine raises $263M for safer immunosuppressantnews2026-08-06T10:30:08+00:00August 6th, 2026|Endpoints News|
